The outlook of companies tied to Viagra's history presents a complex investment picture . While the initial surge generated substantial gains, generic alternatives have significantly eroded revenue. Investing in connected pharmaceutical firms now requires a careful assessment of proprietary rights , evolving medical changes, and the prospect for in